ESMO26: SANOVO data backs 1L Orpathys use in NSCLC subgroup, but AEs temper reaction
Results of two Phase III trials, SANOVO and SAFFRON, with HUTCHMED and AstraZeneca’s Orpathys (savolitinib) were presented recently at the…
Knowledge Bank
